Crystal form of lipoprotein compound and preparation method therefor
Patent Information
- Application Number
- PCT/CN2024/092233
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-25
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-14
Smart Images

Figure PCTCN2024092233-FTAPPB-I100001 
Figure PCTCN2024092233-FTAPPB-I100002 
Figure PCTCN2024092233-FTAPPB-I100003
Abstract
Description
A lipoprotein compound crystal form and preparation method thereof Technical Field
[0001] The present invention relates to the pharmaceutical field and relates to a lipoprotein compound crystal form and a preparation method thereof. Background Art
[0002] Lipoprotein(a) (Lp(a)) is a low-density lipoprotein-like lipid particle, primarily composed of a cholesterol ester-rich core and a unique apolipoprotein(a) (Apo(a)). It exhibits genetic polymorphism and long-term stability, with a skewed distribution across the population. Studies have found that elevated Lp(a) levels are associated with an increased risk of cardiovascular events and related revascularization.
[0003] PCT / CN2022 / 129479 discloses a novel lipoprotein compound, namely (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid (Compound A)
[0004] The crystal structure of a pharmaceutically active ingredient often affects the chemical and physical stability of the drug. Differences in crystallization and storage conditions can lead to variations in the compound's crystal structure, sometimes resulting in the formation of alternative crystalline forms. Generally speaking, amorphous pharmaceutical products lack a regular crystal structure and often exhibit other drawbacks, such as poor product stability, difficulty in filtration, susceptibility to agglomeration, and poor flowability. Therefore, studying their crystal forms is crucial for developing drugs suitable for industrial production and possessing excellent biological activity.
[0005] On the other hand, salt formation can improve certain undesirable physicochemical or biological properties of drugs. The development of salts that exhibit superior physicochemical or pharmaceutical properties compared to (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid is of great significance. Given the importance of solid drug crystal forms and their stability in clinical treatment, in-depth research on the polymorphic forms of pharmaceutically acceptable salts of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propionic acid is also of great significance for the development of drugs suitable for industrial production and with good biological activity.
[0006] Summary of the Invention
[0007] On the one hand, the present disclosure provides a crystalline form A of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle 2θ, having characteristic peaks at 8.343, 18.020, and 21.028.
[0008] In some embodiments, the A crystal form has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 8.343, 12.559, 15.612, 18.020, and 21.028.
[0009] In other embodiments, the X-ray powder diffraction pattern of the crystal form A expressed in terms of a diffraction angle 2θ is shown in FIG2 .
[0010] On the one hand, the present disclosure provides a crystalline form B of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle 2θ, having characteristic peaks at 7.794, 15.530, 19.456, 20.559, and 21.500.
[0011] In some embodiments, the B crystalline form has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 7.794, 11.832, 15.530, 19.456, 20.559, 21.500, and 29.097.
[0012] In some embodiments, the B crystalline form has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 7.794, 11.832, 12.642, 15.530, 19.456, 20.559, 21.500, and 29.097.
[0013] In other embodiments, the X-ray powder diffraction pattern of the B crystal form expressed in terms of a diffraction angle 2θ is shown in FIG3 .
[0014] On the one hand, the present disclosure provides a crystalline form C of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle 2θ, having characteristic peaks at 8.547, 8.847, 13.567, 15.576, and 19.169.
[0015] In some embodiments, the C crystalline form has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 8.547, 8.847, 10.487, 13.567, 15.576, and 19.169.
[0016] In some embodiments, the C crystalline form has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 8.547, 8.847, 10.487, 13.567, 15.576, 19.169, and 21.973.
[0017] In other embodiments, the X-ray powder diffraction pattern of the C crystal form expressed in terms of a diffraction angle 2θ is shown in FIG4 .
[0018] On the one hand, the present disclosure provides a crystalline form D of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle 2θ, having characteristic peaks at 13.834, 16.316, and 20.830.
[0019] In some embodiments, the D crystal form has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 7.928, 13.834, 16.316, and 20.830.
[0020] In other embodiments, the X-ray powder diffraction pattern of the D crystal form expressed in terms of a diffraction angle of 2θ is shown in FIG5 .
[0021] On the one hand, the present disclosure provides a crystalline form E of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle 2θ, having characteristic peaks at 4.933, 6.545, 8.528, 20.874, and 22.149.
[0022] In some embodiments, the E crystalline form has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 4.671, 4.933, 6.545, 8.528, 16.262, 20.874, and 22.149.
[0023] In some embodiments, the E crystalline form has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 4.671, 4.933, 6.545, 8.528, 13.037, 15.017, 16.262, 20.874, and 22.149.
[0024] In other embodiments, the X-ray powder diffraction pattern of the E crystal form expressed in terms of a diffraction angle of 2θ is shown in FIG20 .
[0025] Furthermore, the X-ray powder diffraction patterns of the crystal form A, crystal form B, crystal form C, crystal form D, and crystal form E of compound A disclosed herein are expressed in terms of a diffraction angle 2θ, wherein the error range of the 2θ angle is ±0.2.
[0026] On the other hand, the present disclosure also provides a method for preparing the crystalline form of the aforementioned compound A, which is selected from any of the following methods:
[0027] Method 1:
[0028] (a) mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propionic acid with a solvent, and stirring or heating to dissolve the mixture;
[0029] (b) crystallization;
[0030] Or, method 2:
[0031] (a) mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propionic acid with a solvent, and stirring or heating to dissolve the mixture;
[0032] (b) adding a second solvent and stirring;
[0033] Or, method three:
[0034] (a) mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid with a solvent,
[0035] (b) stirring.
[0036] In certain embodiments, the method for preparing the crystalline form of the aforementioned Compound A described in the present disclosure further comprises any one of the steps of crystallization, filtration, washing or drying.
[0037] In some embodiments, the crystallization includes but is not limited to stirring crystallization (dissolution crystallization, slurry crystallization) and volatile crystallization.
[0038] In some embodiments, the drying method includes but is not limited to forced air drying and vacuum drying. The drying temperature is generally 25°C to 100°C, preferably 30°C to 70°C, such as 40°C, 50°C or 60°C.
[0039] In some embodiments, the method for preparing the aforementioned crystalline form of Compound C comprises (a) mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid with one or more solvents selected from water, isopropanol, tetrahydrofuran, ethanol, acetone, and ethyl acetate;
[0040] (b) beating crystallization, filtering and drying.
[0041] In some embodiments, the method for preparing the aforementioned crystalline form of Compound E comprises (a) mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid with one solvent selected from methanol, ethyl acetate / ethanol (v / v=1:1), and acetonitrile / methanol (v / v=1:1);
[0042] (b) beating crystallization, filtering and drying.
[0043] In another aspect, the present disclosure also provides a pharmaceutically acceptable salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid.
[0044] In some embodiments, the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, succinate, meglumine, maleate, hippurate, sulfate, phosphate, methanesulfonate, tartrate, fumarate, citrate, sodium, potassium, and arginine salts.
[0045] In other embodiments, the chemical ratio of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid to the acid molecule or the base molecule is 1:0.2 to 1:5, preferably 1:0.5, 1:1, 1:2, 1:3 or 1:4.
[0046] In some embodiments, the chemical ratio of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid to the acid molecule is 1:1 to 1:4.
[0047] In some embodiments, the chemical ratio of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and the base molecule is 1:1 to 1:3.
[0048] Some embodiments provide the hydrochloride salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, wherein the chemical ratio of the compound to HCl is 1:1 to 1:3.
[0049] Some embodiments provide the maleate salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, wherein the chemical ratio of the compound to HCl is 1:1.
[0050] Some embodiments provide the L-tartrate salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, wherein the chemical ratio of the compound to L-tartaric acid is 1:1.
[0051] Some embodiments provide a maleate salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, wherein the chemical ratio of the compound to maleic acid is 1:1.
[0052] Some embodiments provide the meglumine salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, wherein the chemical ratio of the compound to meglumine is 1:1 to 1:2.
[0053] The present disclosure also provides a method for preparing the aforementioned pharmaceutically acceptable salt, comprising the step of forming a salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid with an acid or a base.
[0054] In some embodiments, the acid used in the salt-forming reaction is selected from, but not limited to, HCl, succinic acid, maleic acid, hippuric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, tartaric acid, fumaric acid, and citric acid.
[0055] In some embodiments, the base used in the salt-forming reaction is selected from, but not limited to, meglumine salts, sodium hydroxide, potassium hydroxide, and arginine.
[0056] In some embodiments, the solvent used in the salt-forming reaction is selected from at least one of ethanol, ethyl acetate, tetrahydrofuran, acetonitrile, acetone, methanol, 1,4-dioxane, isopropanol, 2-methyltetrahydrofuran, ethylene glycol, and water.
[0057] In certain embodiments, the salt-forming method of the present disclosure further comprises any one of the steps of filtration, washing or drying.
[0058] The present disclosure also provides an α-crystalline form of the potassium salt of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ, and has characteristic peaks at 5.544, 8.016, and 19.356.
[0059] In some embodiments, the potassium salt α-crystalline form has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 5.544, 8.016, 19.356, and 21.537.
[0060] In other embodiments, the X-ray powder diffraction pattern of the potassium salt α-crystalline form expressed in terms of a diffraction angle 2θ is shown in FIG6 .
[0061] The present disclosure also provides a method for preparing the potassium salt α-crystalline form of the aforementioned compound, comprising the steps of mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and ethanol, and (b) adding a potassium hydroxide aqueous solution and stirring.
[0062] The present disclosure also provides an alpha crystalline form of the arginine salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ, and has characteristic peaks at 8.191, 10.598, 15.844, 18.447, and 20.119.
[0063] In some embodiments, the arginine salt a crystal form has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 8.191, 10.598, 15.844, 18.447, 20.119, and 24.226.
[0064] In other embodiments, the X-ray powder diffraction pattern of the arginine salt form a expressed in terms of a diffraction angle 2θ is shown in FIG7 .
[0065] The present disclosure also provides a method for preparing the arginine salt a crystal form of the aforementioned compound, comprising the steps of mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and 10% water / tetrahydrofuran, (b) adding an arginine aqueous solution, and stirring.
[0066] The present disclosure also provides a crystalline form I of the sodium salt of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle 2θ, having characteristic peaks at 13.831 and 18.556.
[0067] In some embodiments, the sodium salt form I has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 7.834, 13.831, 16.194, and 18.556.
[0068] In other embodiments, the X-ray powder diffraction pattern of the sodium salt form I expressed in terms of a diffraction angle of 2θ is shown in FIG8 .
[0069] The present disclosure also provides a method for preparing the sodium salt form I of the aforementioned compound, comprising the steps of mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and 10% water / tetrahydrofuran, and (b) adding a sodium hydroxide solution and stirring.
[0070] The present disclosure also provides a crystalline form a of the meglumine salt of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle 2θ, having characteristic peaks at 5.361, 5.879, 7.118, 8.069, 8.827, and 19.069.
[0071] In some embodiments, the meglumine salt crystalline form a has characteristic peaks at 5.361, 5.879, 7.118, 8.069, 8.827, 9.748, 16.230, and 19.069 in an X-ray powder diffraction pattern expressed as a diffraction angle 2θ.
[0072] In some embodiments, the meglumine salt form a has an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 5.361, 5.879, 7.118, 8.069, 8.827, 9.748, 13.795, 16.230, 19.069, 21.864, and 26.223.
[0073] In other embodiments, the X-ray powder diffraction pattern of the meglumine salt form a expressed in terms of a diffraction angle 2θ is shown in FIG9 .
[0074] The present disclosure also provides a method for preparing the meglumine salt form a of the aforementioned compound, comprising the steps of (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and ethanol, (b) adding a meglumine aqueous solution, and stirring.
[0075] The present disclosure also provides a crystalline form a maleate salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ, and has characteristic peaks at 7.907, 15.612, 19.174, and 20.701.
[0076] In other embodiments, the maleate salt form a has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ as shown in FIG10 .
[0077] The present disclosure also provides a method for preparing the maleate salt form a of the aforementioned compound, comprising the steps of (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and 10% water / tetrahydrofuran, (b) adding an aqueous maleic acid solution, and stirring.
[0078] The present disclosure also provides a hippurate salt form a of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propionic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ, and has characteristic peaks at 5.551, 9.410, 13.522, 14.534, 19.956, 21.337, and 22.945.
[0079] In some embodiments, the hippurate a crystal form has an X-ray powder diffraction pattern expressed as a diffraction angle of 2θ, with characteristic peaks at 5.551, 9.410, 11.209, 13.522, 14.175, 14.534, 19.956, 21.022, 21.337, and 22.945.
[0080] In some embodiments, the hippurate a crystal form has an X-ray powder diffraction pattern expressed as a diffraction angle of 2θ, with characteristic peaks at 5.551, 9.410, 11.209, 13.522, 14.175, 14.534, 16.709, 19.956, 21.022, 21.337, and 22.945.
[0081] In other embodiments, the X-ray powder diffraction pattern of the hippurate salt form a expressed in terms of a diffraction angle 2θ is shown in FIG11 .
[0082] The present disclosure also provides a method for preparing the hippurate salt form a of the aforementioned compound, comprising the steps of mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and ethyl acetate, (b) adding an aqueous hippuric acid solution, and stirring.
[0083] The present disclosure also provides a hippurate β-form of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propionic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ, having characteristic peaks at 4.944, 14.737, 17.143, and 20.109.
[0084] In some embodiments, the hippurate β-crystalline form has characteristic peaks at 4.944, 9.978, 14.737, 17.143, and 20.109 in an X-ray powder diffraction pattern expressed as a diffraction angle 2θ.
[0085] In other embodiments, the hippurate β-crystalline form has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ as shown in FIG12 .
[0086] The present disclosure also provides a method for preparing a hippuric acid salt β-crystalline form of the aforementioned compound, comprising the steps of mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and ethyl acetate, (b) adding an aqueous hippuric acid solution, stirring, and drying. The present disclosure also provides a crystalline form a of the hydrochloride salt of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ, and has characteristic peaks at 6.385, 13.533, 16.203, and 21.244.
[0087] In some embodiments, the hydrochloride salt form a has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 6.385, 8.530, 13.533, 16.203, and 21.244.
[0088] In other embodiments, the X-ray powder diffraction pattern of the hydrochloride salt form a expressed in terms of a diffraction angle 2θ is shown in FIG13 .
[0089] In other embodiments, the chemical ratio of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and HCl in the hydrochloride salt form a is 1:1.
[0090] The present disclosure also provides a method for preparing the hydrochloride salt form a of the aforementioned compound, comprising the steps of mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and a solvent (1), wherein the solvent (1) is selected from methanol, ethyl acetate, and 1,4-dioxane, and (b) adding a hydrochloric acid aqueous solution and stirring.
[0091] The present disclosure also provides a crystalline form b of the hydrochloride salt of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ, having characteristic peaks at 8.059, 10.359, 19.412, 20.726, and 21.843.
[0092] In some embodiments, the hydrochloride salt form b has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 8.059, 10.359, 16.017, 17.806, 19.412, 20.726, and 21.843.
[0093] In other embodiments, the X-ray powder diffraction pattern of the hydrochloride salt form b expressed in terms of a diffraction angle of 2θ is shown in FIG14 .
[0094] In other embodiments, the chemical ratio of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and HCl in the hydrochloride salt form b is 1:1.
[0095] The present disclosure also provides a method for preparing the hydrochloride salt form b of the aforementioned compound, comprising the steps of mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and acetonitrile, (b) adding aqueous hydrochloric acid solution, and stirring.
[0096] The present disclosure also provides a hydrochloride salt form c of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ, having characteristic peaks at 9.395, 11.238, 13.495, and 20.153.
[0097] In some embodiments, the hydrochloride salt form c has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 9.395, 11.238, 13.495, 20.153, 21.169, and 23.125.
[0098] In other embodiments, the X-ray powder diffraction pattern of the hydrochloride salt form c expressed in terms of a diffraction angle of 2θ is shown in FIG15 .
[0099] In other embodiments, the chemical ratio of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and HCl in the hydrochloride salt form c is 1:1.
[0100] The present disclosure also provides a method for preparing the hydrochloride salt form c of the aforementioned compound, comprising the steps of mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and 10% water / tetrahydrofuran, (b) adding aqueous hydrochloric acid solution, and stirring.
[0101] The present disclosure also provides a hydrochloride salt form d of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ, and has characteristic peaks at 8.128, 12.995, 14.962, 16.354, 20.401, and 23.032.
[0102] In some embodiments, the hydrochloride d form has an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 8.128, 12.216, 12.995, 14.962, 16.354, 19.268, 20.401, and 23.032.
[0103] In some embodiments, the hydrochloride d form has an X-ray powder diffraction pattern expressed in a diffraction angle 2θ, with characteristic peaks at 8.128, 12.216, 12.995, 14.962, 16.354, 19.268, 19.965, 20.401, 23.032, and 24.742.
[0104] In other embodiments, the X-ray powder diffraction pattern of the hydrochloride d crystal form expressed in terms of a diffraction angle of 2θ is shown in FIG16 .
[0105] In other embodiments, the chemical ratio of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and HCl in the hydrochloride salt form d is 1:1.
[0106] The present disclosure also provides a method for preparing the hydrochloride salt d form of the aforementioned compound, comprising the steps of mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and 10% water / isopropanol, (b) adding aqueous hydrochloric acid solution, and stirring.
[0107] The present disclosure also provides the hydrochloride form e of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, which has an X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ, with characteristic peaks at 9.385, 14.145, 19.709, 20.277, and 21.583.
[0108] In some embodiments, the hydrochloride salt form e has an X-ray powder diffraction pattern represented by a diffraction angle of 2θ, with characteristic peaks at 9.385, 14.145, 15.451, 19.709, 20.277, 21.583, and 23.684.
[0109] In some embodiments, the hydrochloride salt form e has an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, with characteristic peaks at 9.385, 14.145, 15.451, 19.709, 20.277, 21.583, 23.187, 23.684, and 24.366.
[0110] In other embodiments, the X-ray powder diffraction pattern of the hydrochloride form e expressed in terms of a diffraction angle of 2θ is shown in FIG17 .
[0111] In other embodiments, the chemical ratio of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and HCl in the hydrochloride salt form e is 1:1.
[0112] The present disclosure also provides a method for preparing the hydrochloride salt form e of the aforementioned compound, comprising the steps of mixing the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and a solvent (2), wherein the solvent (2) is selected from 10% water / isopropanol, acetonitrile, 10% water / tetrahydrofuran, methanol, isopropanol, or a mixed solvent thereof; and (b) adding an aqueous hydrochloric acid solution, stirring, and drying.
[0113] Furthermore, the crystalline form of the pharmaceutically acceptable salt of Compound A disclosed herein has an X-ray powder diffraction pattern expressed as a diffraction angle 2θ, wherein the error range of the 2θ angle is ±0.2. In certain embodiments, the method for preparing the crystalline form disclosed herein comprises any step of filtration (or centrifugal filtration / centrifugation), washing, or drying.
[0114] In some embodiments, the drying method includes but is not limited to forced air drying and vacuum drying. The drying temperature is generally 25°C to 100°C, preferably 30°C to 70°C, such as 40°C, 50°C or 60°C.
[0115] On the other hand, the present disclosure also provides a pharmaceutical composition comprising the aforementioned crystal form and a pharmaceutically acceptable excipient.
[0116] The present disclosure also provides a pharmaceutical composition prepared from the aforementioned crystal form and a pharmaceutically acceptable excipient.
[0117] The present disclosure also provides a method for preparing a pharmaceutical composition, comprising the step of mixing the aforementioned crystal form with a pharmaceutically acceptable excipient.
[0118] The present disclosure also provides use of the aforementioned pharmaceutically acceptable salt, the aforementioned crystal form or the aforementioned pharmaceutical composition in the preparation of a medicament for preventing and / or treating a disease or condition associated with elevated LP(a) plasma levels.
[0119] The present disclosure also provides use of the aforementioned pharmaceutically acceptable salt, the aforementioned crystal form or the aforementioned pharmaceutical composition in the preparation of a medicament for preventing and / or treating cardiovascular diseases.
[0120] The "2θ or 2θ angle" mentioned in the present disclosure refers to the diffraction angle, θ is the Bragg angle, and the unit is ° or degree; the error range of each characteristic peak 2θ is ±0.20 (including the case where the number exceeding 1 decimal place is rounded off), specifically -0.20, -0.19, -0.18, -0.17, -0.16, -0.15, -0.14, -0.13, -0.12, -0.11, -0.10, -0.09, -0.08, -0.07, -0.06, -0.05, -0.04, -0.03, -0.02, -0.01, 0.00, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20.
[0121] The numerical values in this disclosure are instrumental measurements or calculated values after instrumental measurement, and are subject to a certain degree of error. Generally speaking, a value within a reasonable error range of plus or minus 10% is within the reasonable error range. Of course, the context in which the numerical value is used must be considered. For example, the total impurity content, which is a value with an error variation of no more than plus or minus 10% after measurement, can be plus or minus 9%, plus or minus 8%, plus or minus 7%, plus or minus 6%, plus or minus 5%, plus or minus 4%, plus or minus 3%, plus or minus 2%, or plus or minus 1%, preferably plus or minus 5%.
[0122] The "differential scanning calorimetry or DSC" described in this disclosure refers to measuring the temperature difference and heat flow difference between a sample and a reference object during the process of heating or maintaining the sample at a constant temperature to characterize all physical and chemical changes related to thermal effects and obtain phase change information of the sample.
[0123] The "pharmaceutically acceptable excipients" described in this disclosure include, but are not limited to, any adjuvant, carrier, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent or emulsifier approved by the U.S. Food and Drug Administration for use by humans or livestock animals.
[0124] The "beating" mentioned in the present disclosure refers to a purification method that utilizes the property that a substance has poor solubility in a solvent but impurities have good solubility in a solvent. Beating purification can remove color, change the crystal form or remove a small amount of impurities.
[0125] The crystalline forms disclosed herein include but are not limited to solvates of Compound A, and the solvents include but are not limited to water. BRIEF DESCRIPTION OF THE DRAWINGS
[0126] Figure 1 is the XRPD spectrum of the amorphous form of compound A.
[0127] Figure 2 is the XRPD spectrum of Form A of Compound A.
[0128] Figure 3 is the XRPD spectrum of Form B of Compound A.
[0129] Figure 4 is the XRPD spectrum of Form C of Compound A.
[0130] Figure 5 is an XRPD spectrum of Form D of Compound A. Figure 6 is an XRPD spectrum of Form α of the potassium salt of Compound A.
[0131] FIG7 is an XRPD spectrum of Compound A arginine salt form a.
[0132] FIG8 is an XRPD spectrum of Compound A sodium salt Form I.
[0133] FIG9 is an XRPD spectrum of Compound A meglumine salt Form a.
[0134] Figure 10 is an XRPD spectrum of Compound A maleate salt Form a.
[0135] FIG11 is an XRPD spectrum of Compound A hippurate salt form a.
[0136] FIG12 is an XRPD spectrum of the β-form hippurate of Compound A.
[0137] FIG13 is an XRPD spectrum of Compound A hydrochloride Form a.
[0138] Figure 14 is the XRPD spectrum of Compound A hydrochloride Form b.
[0139] Figure 15 is the XRPD spectrum of Compound A hydrochloride Form c.
[0140] Figure 16 is the XRPD spectrum of Compound A hydrochloride Form d.
[0141] Figure 17 is the XRPD spectrum of Compound A hydrochloride Form e.
[0142] FIG18 is an XRPD spectrum of the amorphous form of Compound A hydrochloride (1:4).
[0143] FIG19 is an XRPD spectrum of the amorphous form of Compound A hydrochloride (1:1).
[0144] Figure 20 is the XRPD spectrum of Form E of Compound A. DETAILED DESCRIPTION
[0145] The present disclosure is further described in detail by the following examples and experimental examples. These examples and experimental examples are for illustrative purposes only and are not intended to limit the scope of the present disclosure.
[0146] Test conditions of the instruments used in the experiment:
[0147] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). -6 The unit of ppm is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD), and tetramethylsilane (TMS) was used as the internal standard.
[0148] MS measurements were performed using an Agilent 1200 / 1290 DAD-6110 / 6120 Quadrupole MS liquid chromatography-mass spectrometer (manufacturer: Agilent, MS model: 6110 / 6120 Quadrupole MS), a Waters ACQuity UPLC-QD / SQD (manufacturer: Waters, MS model: Waters ACQuity Qda Detector / Waters SQ Detector), and a THERMO Ultimate 3000-Q Exactive (manufacturer: THERMO, MS model: THERMO Q 15 Exactive).
[0149] HPLC analysis was performed using an Agilent 1260DAD high pressure liquid chromatograph (Sunfire C18 150×4.6 mm column) and a Thermo U3000 high pressure liquid chromatograph (Gimini C18 150×4.6 mm column).
[0150] XRPD is X-ray powder diffraction detection: the measurement is carried out using a BRUKER D8 X-ray diffractometer, specific collection information: Cu anode (40kV, 40mA), radiation: monochromatic Cu-Ka radiation Scanning mode: θ / 2θ, scanning range: 3-48°.
[0151] DSC is differential scanning calorimetry: the measurement was performed using a METTLER TOLEDO DSC 3+ differential scanning calorimeter with a heating rate of 10°C / min, from 25 to 300°C or from 25 to 350°C, and a nitrogen purge rate of 50 mL / min.
[0152] TGA is thermogravimetric analysis: the test was performed using a METTLER TOLEDO TGA 2 thermogravimetric analyzer with a heating rate of 10°C / min. The specific temperature range was referred to the corresponding spectrum, and the nitrogen purge rate was 50 mL / min.
[0153] DVS stands for dynamic moisture sorption: using the Surface Measurement Systems instrument, humidity starts at 50% and the humidity range is 0%-95% with a step of 10%. The judgment standard is that the mass change of each gradient dM / dT is ≤ 0.002%, TMAX is 360min, and there are two cycles.
[0154] The known starting materials disclosed herein can be synthesized by methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, Darui Chemicals, etc.
[0155] The reaction progress in the examples was monitored by thin layer chromatography (TLC). The developing solvents used in the reactions, the eluent systems for column chromatography used to purify the compounds, and the developing solvent systems for the thin layer chromatography included: A: dichloromethane / methanol system, B: n-hexane / ethyl acetate system. The volume ratio of the solvents was adjusted according to the polarity of the compounds, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid could also be added for adjustment.
[0156] Example 1
[0157] (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid tetrahydrochloride
[0158] Step 1: Preparation of (R)-tert-butyl 3-((S)-1-((S)-4-benzyl-2-oxooxazolidin-3-yl)-3-(3-(benzyloxy)phenyl)-1-oxopropan-2-yl)pyrrolidine-1-carboxylate (6a)
[0159] Under a nitrogen atmosphere, 1b (10.0 g, 25.74 mmol) was dissolved in tetrahydrofuran (10 mL), cooled to -30°C, and a 1M solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (31 mL, 31 mmol) was added dropwise. The reaction was allowed to proceed for 30 minutes after the addition was complete. A solution of 3-benzyloxybenzyl bromide (8.56 g, 30.89 mmol) in tetrahydrofuran (15 mL) was then added dropwise. The reaction was allowed to proceed for 1 hour, and the temperature was raised to 0-5°C and allowed to react overnight. Saturated ammonium chloride solution (50 mL) was added, and the mixture was extracted with methyl tert-butyl ether (50 mL x 2). The mixture was washed with saturated sodium chloride solution (70 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography (petroleum ether:ethyl acetate = 4:1) to obtain the title product 6a (7.08 g, 47.0% yield).
[0160] Step 2: Preparation of (S)-3-(3-(benzyloxy)phenyl)-2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl)propanoic acid (6b)
[0161] 6a (7 g, 11.983 mmol) was dissolved in tetrahydrofuran (70 mL) and water (35 mL). Hydrogen peroxide (30%) (4.07 g, 35.95 mmol) and lithium hydroxide monohydrate (431 mg, 17.97 mmol) were added and reacted at room temperature overnight. The pH was adjusted to >13 with 2M sodium hydroxide solution, and the mixture was extracted with methyl tert-butyl ether (50 mL x 2). The aqueous phase was adjusted to pH <3 with 2M hydrochloric acid solution, extracted with methyl tert-butyl ether (50 mL x 2), washed with saturated sodium chloride solution (70 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain 3.11 g of crude product 6b, which was directly used in the next step without purification.
[0162] Step 3: Preparation of tert-butyl (R)-3-((S)-3-(3-(benzyloxy)phenyl)-1-(tert-butoxy)-1-oxopropan-2-yl)pyrrolidine-1-carboxylate (6c)
[0163] The crude product 6b (3.1 g, 7.29 mmol) from the previous step was dissolved in 2-methyltetrahydrofuran (60 mL), followed by the addition of 2-tert-butyl-1,3-diisopropylisourea (5.84 g, 29.14 mmol). The reaction was heated to 65°C and allowed to react overnight. The mixture was filtered, and the filtrate was concentrated to dryness under reduced pressure. The resulting residue was purified by column chromatography (petroleum ether:ethyl acetate = 5:1) to afford product 6c (2.5 g, two-step yield: 43.3%).
[0164] Step 4: Preparation of (R)-tert-butyl 3-((S)-1-(tert-butoxy)-3-(3-hydroxyphenyl)-1-oxopropan-2-yl)pyrrolidine-1-carboxylate (6d)
[0165] Under hydrogen atmosphere, 6c (2.5 g, 5.19 mmol) was dissolved in MeOH (40 mL), and Pd / C (0.80 g) was added. The mixture was reacted at room temperature overnight, filtered, and concentrated under reduced pressure to give product 6d (1.78 g, yield: 87.6%).
[0166] Step 5: Preparation of tert-butyl (R)-3-((S)-3-(3-(2-(((benzyloxy)carbonyl)amino)ethoxy)phenyl)-1-(tert-butoxy)-1-oxopropan-2-yl)pyrrolidine-1-carboxylate (6e)
[0167] 6d (400 mg, 0.99 mmol), benzyl N-(2-bromoethyl)carbamate (280 mg, 1.09 mmol), and cesium carbonate (803 mg, 2.47 mmol) were added to N,N-dimethylformamide (8 mL) and heated to 80°C for 3 hours. Water (40 mL) was added, and the mixture was extracted with ethyl acetate (30 mL × 2). The mixture was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under pressure to obtain a residue. The residue was purified by column chromatography (petroleum ether:ethyl acetate = 8:1) to obtain product 6e (300 mg, 53.5% yield).
[0168] Step 6: Preparation of (R)-tert-butyl 3-((S)-3-(3-(2-aminoethoxy)phenyl)-1-(tert-butoxy)-1-oxopropan-2-yl)pyrrolidine-1-carboxylate (6f)
[0169] Under hydrogen atmosphere, 6e (300 mg, 0.528 mmol) was dissolved in MeOH (5 mL), and Pd / C (100 mg) was added. The mixture was reacted at room temperature overnight, filtered, and concentrated under reduced pressure to afford product 6f (150 mg, 65.4% yield).
[0170] Step 7: Preparation of tert-butyl (3R)-3-[(2S)-1-(tert-butoxy)-3-(3-{[(2-{3-[(2S)-3-(tert-butoxy)-2-[(3R)-1-[(tert-butoxy)carbonyl]pyrrolidin-3-yl]-3-oxopropyl]phenoxy}ethyl)({3-[(2S)-3-(tert-butoxy)-2-[(3R)-1-[(tert-butoxy)carbonyl]pyrrolidin-3-yl]-3-oxopropyl]phenyl}methyl)amino]methyl}phenyl)-1-oxopropan-2-yl]pyrrolidine-1-carboxylate (6 g)
[0171] Under ice, 6f (150 mg, 0.35 mmol) and 4a (278.6 mg, 0.69 mmol) were dissolved in isopropanol (6 mL) and 1 drop of glacial acetic acid was added. The mixture was allowed to react for 30 minutes. Sodium triacetoxyborohydride (292.6 mg, 1.38 mmol) was added, the temperature was slowly warmed to room temperature, and the reaction was allowed to proceed overnight. The pH was adjusted to 8-9 with saturated sodium bicarbonate solution, and the mixture was extracted with ethyl acetate (40 mL x 2), washed with saturated sodium chloride solution (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to afford 480 mg of the crude product. Purification by preparative liquid chromatography afforded 6 g of the product (250 mg, 59.9% yield).
[0172] Step 8: Preparation of (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid tetrahydrochloride
[0173] 6 g (100 mg, 0.083 mmol) was added to a 4 M hydrochloric acid solution in dioxane (4 mL) and stirred at room temperature overnight. The supernatant was decanted to obtain a solid, which was washed with ethyl acetate and lyophilized to obtain the title product (50 mg, 68.5% yield). X-ray powder diffraction analysis revealed no distinct characteristic peaks, as shown in Figure 18, indicating that the product was amorphous.
[0174] MS m / z(ESI):741.3[M+H] + .
[0175] 1 H NMR (400MHz, D2O): δ7.42-7.16(m,9H),6.86(d,J=7.6Hz,1H),6.70(dd,J=8.3,2.6Hz,1H),6.65(s,1H),4.43(s,4H),4.14-3.97(m,2H),3.62-3. 45(m,5H),3.45-3.30(m,3H),3.29-3.14(m,3H),3.07-2.98(m,3H),2.9 3-2.63(m,9H),2.61-2.39(m,3H),2.24-2.02(m,3H),1.78-1.64(m,3H).
[0176] 1 g of the hydrochloride prepared according to the above example was added to an aqueous sodium bicarbonate solution (4 eq., 5.4 mmol, approximately 0.45 g of sodium bicarbonate). The mixture was stirred for 2-4 hours, and the mixture was purified by reverse phase chromatography on a C18 column (gradient elution with acetonitrile / water in a ratio of 1:9 to 1:1). The mixture was then lyophilized to obtain (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid (Compound A). X-ray powder diffraction analysis revealed no obvious characteristic peaks in the X-ray powder diffraction spectrum, as shown in Figure 1, indicating that the compound was amorphous.
[0177] Preparation of Intermediate 1b: Preparation of tert-butyl (R)-3-(2-((S)-4-benzyl-2-oxooxazolidin-3-yl)-2-oxoethyl)pyrrolidine-1-carboxylate (1b)
[0178] Dissolve (R)-N-tert-Butyloxycarbonyl-3-tetrahydropyrrolacetic acid 1a (9 g, 39 mmol) in anhydrous tetrahydrofuran (100 mL), cool to 0°C, add triethylamine (13.6 mL, 98 mmol), and stir at 0°C for 5 minutes. Add pivaloyl chloride (5.8 g, 47.1 mmol) without exceeding 10°C. Stir for 15 minutes, then add lithium chloride (1.9 g, 47.1 mmol) and a solution of (S)-4-benzyl-2-oxazolidinone (6.9 g, 39 mmol) in tetrahydrofuran (100 mL). Warm the reaction mixture to room temperature and stir for 24 hours. Add 2M aqueous hydrochloric acid (500 mL), separate the organic phase, concentrate, and purify the residue by silica gel flash column chromatography (petroleum ether / ethyl acetate) to afford 1b (12.5 g, 82% yield) as an oily liquid.
[0179] MS (ESI): m / z = 411.1 [M + Na] + .
[0180] Preparation of Intermediate 4a: Preparation of tert-butyl (R)-3-((S)-1-(tert-butoxy)-3-(3-formylphenyl)-1-oxopropan-2-yl)pyrrolidine-1-carboxylate (4a)
[0181] 3a, prepared according to Preparation 16 in patent WO2020247429, N-formyl saccharin (428 mg, 2.0 mmol), palladium acetate (40 mg, 0.2 mmol), 1,4-bis(diphenylphosphino)butane (83 mg, 0.2 mmol), and triethylsilane (0.24 mL, 1.5 mmol) were added to a microwave reaction tube, followed by N,N-dimethylformamide (6 mL). After nitrogen replacement, the reaction was allowed to proceed at 75°C overnight. After completion of the reaction as monitored by LCMS, the reaction solution was cooled to room temperature, centrifuged, and the filtrate was purified by reverse phase flash column chromatography (acetonitrile / water) to obtain 4a as a yellow oil (270 mg, 76% yield).
[0182] MS (ESI): m / z = 404.5 [M+H] + .
[0183] Test Example 1: Compound Inhibition Activity Test for Lp(a) Assembly
[0184] The present disclosure utilizes a dual-antibody ELISA method to detect the assembly efficiency of Apo(a) and ApoB proteins. The antibodies are ApoB-Capture antibody (Mabtech) and Apo(a)-Detector antibody (Abcam). The test samples are plasma from human transgenic hApo(a) and hApoB mice, respectively, diluted 500-fold.
[0185] Experimental steps: Equal amounts of Apo(a) and ApoB serum were mixed with gradient dilutions (maximum concentration 100nM, 3-fold gradient dilution) of the test compound, the mixture was incubated in a 37°C incubator for 2 hours, and then EACA with a final concentration of 150mM was added to terminate the reaction. The reaction solution was added to the ELISA detection plate pre-coated with ApoB-Capture antibody, incubated at room temperature for 2 hours, and then the plate was washed 4 times with washing solution; biotin-labeled Apo(a)-Detector antibody was added, incubated at room temperature for 1 hour, the plate was washed and the color development substrate TMB solution was added; after incubation at room temperature for 15 minutes, the reaction termination solution was added, mixed and the absorbance at 450nm was immediately detected with an enzyme reader. Finally, GraphPad Prism 9 software was used for data analysis and IC 50 Calculation.
[0186] 0% inhibition of the assembly of Apo(a) and ApoB proteins corresponds to the OD value when the compound concentration is 0 (1% DMSO); 100% inhibition of the assembly of Apo(a) and ApoB proteins corresponds to the OD value when only ApoB protein solution (hApoB mouse plasma dilution) is added. 50 =0.41nM.
[0187] Test Example 2: In vivo pharmacokinetic study in beagle dogs
[0188] Beagle dogs were used as test animals, and the drug concentration in the plasma of the disclosed compound at different time points after oral administration was determined by LC / MS / MS. The pharmacokinetic behavior of the disclosed compound in beagle dogs was studied and its pharmacokinetic characteristics were evaluated.
[0189] Experimental animals: 2 healthy male beagle dogs aged 8 to 36 months per group
[0190] Drug preparation: Weigh a certain amount of drug and add normal saline to make a 2 mg / mL colorless clear solution.
[0191] Administration: Beagle dogs were fasted overnight and then gavage was used to administer the drug. The dosage of Reference Material 1 and the compound of Example 6 was 10 mg / kg.
[0192] Procedure: Beagle dogs were orally administered with the disclosed compounds. Approximately 0.6 mL of blood was collected by peripheral venipuncture at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after administration. The blood was placed in a tube containing EDTA-K2 and centrifuged at 2000 rpm for 10 minutes at approximately 4°C to separate the plasma, which was then stored at -75°C.
[0193] The content of the test compound in beagle dog plasma at different blood collection time points was determined: 33 μL of beagle dog plasma (30 μL plasma and 3 μL blank) collected at each time point after administration was added to 18 μL of 6% perchloric acid solution, vortexed for 30 seconds, and centrifuged at 3900 rpm at 4°C for 15 minutes. Then, 200 μL of alkaline (ammonia water adjusted to pH 10-11) acetonitrile solution containing internal standard dexamethasone was added to precipitate the protein. The mixture was vortexed for 30 seconds and centrifuged at 3900 rpm at 4°C for 15 minutes. The supernatant of the plasma sample was taken, diluted 3-fold with water, and 8 μL was used for LC / MS / MS analysis.
[0194] Pharmacokinetic parameter results
[0195] After LC / MS / MS analysis to determine the blood drug concentration, pharmacokinetic parameters were calculated using WinNonlin 6.1 software and the non-compartmental model method. The pharmacokinetic parameters of the disclosed compounds in beagle dogs are shown in Table 1.
[0196] Table 1 Pharmacokinetic parameters of the disclosed compounds in beagle dogs after oral administration
[0197] Conclusion: The disclosed compounds have better oral absorption, better systemic exposure, longer half-life, and excellent pharmacokinetic characteristics, and oral administration has obvious advantages.
[0198] Reference 1 is the compound of Example 1 in patent CN114008021, which was obtained according to the preparation method of Example 1 in patent CN114008021.
[0199] Example 2: Preparation of Form A of Compound A
[0200] 5 mg of compound A (prepared according to the method of Example 1) was taken and placed under 93% RH. X-ray powder diffraction analysis showed that the product was defined as Form A. The XRPD spectrum is shown in Figure 2, and the positions of its characteristic peaks are shown in Table 2.
[0201] Table 2
[0202] Example 3: Preparation of Form B of Compound A
[0203] 100 mg of compound A (prepared according to the method of Example 1) was taken, 1.0 mL of water was added, and the mixture was slurried at room temperature and centrifuged to obtain the product.
[0204] The product was defined as Form B by X-ray powder diffraction analysis. The XRPD spectrum is shown in FIG3 , and the positions of the characteristic peaks are shown in Table 3 .
[0205] Table 3
[0206] Example 4: Preparation of Form C of Compound A
[0207] 100 mg of compound A (prepared according to the method of Example 1) was added to 1.0 mL of water, slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0208] The product was defined as Form C by X-ray powder diffraction analysis. The XRPD spectrum is shown in FIG4 , and the positions of the characteristic peaks are shown in Table 4 .
[0209] Table 4
[0210] Example 5: Preparation of Form C of Compound A
[0211] 10 mg of compound A (prepared according to the method of Example 1) was added to 0.1 mL of the solvent shown in Table 5, and the mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0212] Table 5
[0213] Example 6: Preparation of Form C of Compound A
[0214] 5 mg of compound A (prepared according to the method of Example 1) was added to 0.3 mL of tetrahydrofuran / ethyl acetate (v / v=2:1), and 1.2 mL of water. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0215] Example 7: Preparation of Form D of Compound A
[0216] 50 mg of compound A (prepared according to the method of Example 1) was added to 0.5 mL of 10% water / tetrahydrofuran, slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0217] The XRPD spectrum of the product was shown in FIG5 and the positions of the characteristic peaks were shown in Table 6. The product was defined as the free-state D crystal form.
[0218] The DSC spectrum showed endothermic peaks at 65.77 and 256.41°C, and TGA showed a weight loss of 9.9% in the range of 31-221°C.
[0219] Table 6
[0220] Example 8: Preparation of potassium salt α crystal form
[0221] 10 mg of compound A was added to 0.2 mL of ethanol, and then 28 μL of 2 M potassium hydroxide aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0222] The product was defined as potassium salt α-crystalline form by X-ray powder diffraction analysis. The XRPD spectrum is shown in FIG6 , and the positions of its characteristic peaks are shown in Table 7.
[0223] Table 7
[0224] Example 9: Preparation of Arginine Salt Form A
[0225] 5 mg of compound A was added to 0.1 mL of 10% water / tetrahydrofuran, and then 14 μL of 1 M arginine aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0226] The product was defined as arginine salt a crystal form by X-ray powder diffraction analysis. The XRPD spectrum is shown in FIG7 , and the positions of the characteristic peaks are shown in Table 8.
[0227] Table 8
[0228] Example 10: Preparation of Sodium Salt Form I
[0229] 10 mg of compound A was added to 0.2 mL of 10% water / tetrahydrofuran, and then 8 μL of 2M sodium hydroxide aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0230] The product was defined as sodium salt Form I by X-ray powder diffraction analysis. The XRPD spectrum is shown in FIG8 , and the positions of the characteristic peaks are shown in Table 9.
[0231] Table 9
[0232] Example 11: Preparation of Crystal Form a of Meglumine Salt
[0233] 10 mg of compound A was added to 0.2 mL of ethanol, and then 57 μL of 1 M meglumine aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0234] The product was defined as meglumine salt form a by X-ray powder diffraction analysis. The XRPD spectrum is shown in FIG9 , and the positions of the characteristic peaks are shown in Table 10.
[0235] Table 10
[0236] Example 12: Preparation of amorphous sodium salt
[0237] 5 mg of compound A was added to 0.1 mL of ethyl acetate, and then 7 μL of 2 M sodium hydroxide aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0238] X-ray powder diffraction analysis showed that the XRPD spectrum had no obvious characteristic peaks, indicating that the product was an amorphous sodium salt.
[0239] Example 13: Preparation of amorphous arginine salt
[0240] 5 mg of compound A was added to 0.1 mL of ethyl acetate, and then 14 μL of 1 M arginine aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0241] X-ray powder diffraction analysis showed that the XRPD spectrum had no obvious characteristic peaks, indicating that the product was an amorphous arginine salt.
[0242] Example 14: Preparation of amorphous meglumine salt
[0243] 5 mg of compound A was added to 0.1 mL of ethanol, and then 14 μL of 1 M meglumine aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0244] X-ray powder diffraction analysis showed that the XRPD spectrum had no obvious characteristic peaks, indicating that the product was amorphous meglumine salt.
[0245] Example 15: Preparation of Maleate Salt Form A
[0246] 10 mg of compound A was added to 0.2 mL of 10% water / tetrahydrofuran, and then 14 μL of 1 M maleic acid aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0247] The product was defined as maleate salt a crystal form by X-ray powder diffraction analysis. The XRPD spectrum is shown in FIG10 , and the positions of the characteristic peaks are shown in Table 11.
[0248] Table 11
[0249] Example 16: Preparation of Hippurate α Crystalline Form
[0250] 5 mg of compound A was added to 0.1 mL of ethyl acetate, and then 14 μL of 1 M hippuric acid aqueous solution was added. The mixture was slurried at room temperature and centrifuged to obtain the product.
[0251] The product was defined as hippurate α-crystal by X-ray powder diffraction analysis. The XRPD spectrum is shown in FIG11 , and the positions of the characteristic peaks are shown in Table 12.
[0252] Table 12
[0253] Example 17: Preparation of hippurate β-crystalline form
[0254] 5 mg of compound A was added to 0.1 mL of ethyl acetate, and then 14 μL of 1 M hippuric acid aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0255] X-ray powder diffraction analysis revealed that the product was defined as hippurate β-crystal. The XRPD spectrum is shown in FIG12 , and the positions of the characteristic peaks are shown in Table 13 .
[0256] Table 13
[0257] Example 18: Preparation of Sulfate Amorphous Form
[0258] 5 mg of compound A was added to 0.1 mL of 10% water / tetrahydrofuran, and then 8 μL of 1.8 M aqueous sulfuric acid solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0259] X-ray powder diffraction analysis showed that the XRPD spectrum had no characteristic peaks, indicating that the product was an amorphous sulfate.
[0260] Example 19: Preparation of amorphous phosphate
[0261] 5 mg of compound A was added to 0.1 mL of ethanol, and then 10 μL of 1.5 M phosphoric acid aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0262] X-ray powder diffraction analysis showed that the XRPD spectrum had no characteristic peaks, indicating that the product was an amorphous phosphate.
[0263] Example 20: Preparation of amorphous methanesulfonate
[0264] 5 mg of compound A was added to 0.1 mL of ethanol, and then 9 μL of 1.5 M methanesulfonic acid aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0265] X-ray powder diffraction analysis showed that the XRPD spectrum had no characteristic peaks, indicating that the product was an amorphous methanesulfonate.
[0266] Example 21: Preparation of amorphous maleate
[0267] 5 mg of compound A was added to 0.1 mL of ethanol, and then 14 μL of 1 M maleic acid aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0268] X-ray powder diffraction analysis showed that the XRPD spectrum had no characteristic peaks, indicating that the product was an amorphous maleate salt.
[0269] Example 22: Preparation of amorphous fumarate
[0270] 5 mg of compound A was added to 0.1 mL of ethanol, and then 21 μL of 0.7 M fumaric acid methanol solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0271] X-ray powder diffraction analysis showed that the XRPD spectrum had no characteristic peaks, indicating that the product was an amorphous fumarate.
[0272] Example 23: Preparation of amorphous citrate
[0273] 5 mg of compound A was added to 0.1 mL of ethanol, and then 14 μL of 0.7 M citric acid aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0274] X-ray powder diffraction analysis showed that the XRPD spectrum had no characteristic peaks, indicating that the product was an amorphous citrate.
[0275] Example 24: Preparation of Hydrochloride (1:1) a Crystalline Form
[0276] 10 mg of compound A was added to 0.07 mL of methanol, and then 9 μL of 5 M hydrochloric acid solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0277] The product was defined as hydrochloride salt form a by X-ray powder diffraction analysis. The XRPD spectrum is shown in FIG13 , and the positions of the characteristic peaks are shown in Table 14 .
[0278] The DSC spectrum showed endothermic peaks at 59.78 and 285.05°C. TGA analysis revealed a 4.4% weight loss in the 32-160°C range. Ion chromatography analysis revealed a chloride ion content of 4.75%. DVS hygroscopicity testing revealed a 30% weight gain at 80% relative humidity.
[0279] Table 14
[0280] Example 25: Preparation of Hydrochloride (1:1) a Crystalline Form
[0281] 10 mg of compound A was added to 0.07 mL of ethyl acetate, and then 9 μL of 5 M hydrochloric acid solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the target product.
[0282] Example 26: Preparation of Hydrochloride (1:1) Form a
[0283] 10 mg of compound A was added to 0.07 mL of 1,4-dioxane, and then 9 μL of 5 M aqueous hydrochloric acid solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the target product.
[0284] Example 27: Preparation of Hydrochloride Form b
[0285] 10 mg of compound A was added to 0.07 mL of acetonitrile, and then 9 μL of 5 M hydrochloric acid aqueous solution was added. The mixture was slurried at room temperature and centrifuged to obtain the product.
[0286] The product was defined as hydrochloride b crystal form by X-ray powder diffraction analysis. The XRPD spectrum is shown in FIG14 , and the positions of its characteristic peaks are shown in Table 15 .
[0287] Table 15
[0288] Example 28: Preparation of Hydrochloride (1:1) Form c
[0289] 10 mg of compound A was added to 0.07 mL of 10% water / tetrahydrofuran (v / v), and then 9 μL of 5 M hydrochloric acid aqueous solution was added. The mixture was slurried at room temperature and centrifuged to obtain the product.
[0290] The product was defined as hydrochloride c crystal form by X-ray powder diffraction analysis. The XRPD spectrum is shown in FIG15 , and the positions of its characteristic peaks are shown in Table 16 .
[0291] The DSC spectrum showed endothermic peaks at 70.77, 114.11, 147.43, 227.41, and 282.72°C. The TGA showed a weight loss of 3.8% in the range of 32-122°C and a weight loss of 4.2% in the range of 122-225°C.
[0292] Table 16
[0293] Example 29: Preparation of Hydrochloride (1:1) Form d
[0294] 10 mg of compound A was added to 0.07 mL of 10% water / isopropanol, and then 9 μL of 5 M hydrochloric acid aqueous solution was added. The mixture was slurried at room temperature and centrifuged to obtain the product.
[0295] X-ray powder diffraction analysis revealed that the product was defined as hydrochloride d-form. The XRPD spectrum was shown in FIG16 , and the positions of the characteristic peaks were shown in Table 17 .
[0296] The DSC spectrum showed endothermic peaks at 97.05, 117.48, 142.73, and 284.01°C, and the TGA showed a weight loss of 6.3% in the range of 33-138°C.
[0297] Table 17
[0298] Example 30: Preparation of hydrochloride (1:1) e crystal form
[0299] 100 mg of compound A was added to 0.6 mL of 10% water / isopropanol, and then 27 μL of 5 M hydrochloric acid aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the product.
[0300] X-ray powder diffraction analysis showed that the product was defined as hydrochloride form e. The XRPD spectrum was shown in FIG17 , and the positions of the characteristic peaks were shown in Table 18.
[0301] The DSC spectrum showed endothermic peaks at 76.58, 108.43, 146.76, and 287.37°C, and the TGA showed a weight loss of 6.1% in the range of 30-161°C.
[0302] Ion chromatography showed that the chloride ion content was 5.20%. DVS hygroscopicity test results showed that the weight gain was 18% at 80% RH.
[0303] Table 18
[0304] Example 31: Preparation of Hydrochloride Form e
[0305] 10 mg of compound A was added to 0.6 mL of acetonitrile, and then 2.7 μL of 5 M hydrochloric acid aqueous solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the target product.
[0306] Example 32: Preparation of Hydrochloride Form e
[0307] 100 mg of compound A was added to 0.6 mL of 10% water / tetrahydrofuran (v / v), and then 27 μL of 5 M aqueous hydrochloric acid solution was added. The mixture was slurried at room temperature, centrifuged, and the solid was dried to obtain the target product.
[0308] Example 33: Preparation of Hydrochloride Form e
[0309] 2 g of compound A was added to 6.0 mL of water and 10.0 mL of methanol, and then 540 μL of 5 M aqueous hydrochloric acid solution was added. The solution was added to 20.0 mL of isopropanol, slurried at room temperature, centrifuged, and the solid was dried to obtain the target product.
[0310] Example 34: Preparation of amorphous hydrochloride (1:1)
[0311] 125 mg of Compound A hydrochloride Form d was added to 2.5 mL of acetonitrile, slurried at room temperature, centrifuged, and the solid dried to obtain the desired product. X-ray powder diffraction analysis revealed the product to be an amorphous monohydrochloride salt. The XRPD spectrum is shown in Figure 19.
[0312] Example 35: Preparation of amorphous hydrochloride (1:4)
[0313] 5 mg of the tetrahydrochloride sample of Compound A prepared in Example 1 was added to the solvents listed in Table 19, slurried at room temperature, and observed for crystallization. If solid formed, the product was centrifuged and dried to obtain a solid product. X-ray powder diffraction analysis revealed the relevant data shown in Table 19.
[0314] Table 19
[0315] Note: The XRPD spectrum of sample a is shown in Figure 18. The DVS hygroscopicity test results show that the weight gain is 34% at 80% RH.
[0316] Example 35: Preparation of Form E
[0317] 10 mg of Compound A (prepared according to Example 1) was added to 0.5 ml of methanol and slurried at 25°C for 4 days. The solid was centrifuged and dried to obtain the product. X-ray powder diffraction analysis identified this product as Form E. The XRPD spectrum is shown in Figure 20 , and the positions of its characteristic peaks are shown in Table 20.
[0318] The DSC spectrum showed an endothermic peak at 247.23°C and a weight loss of 3.58% in the range of 36-90°C by TGA.
[0319] Table 20
[0320] Example 36: Preparation of Form E
[0321] 10 mg of compound A (prepared according to the method of Example 1) was added to 0.5 ml of methanol, and the mixture was slurried at 50° C. for 1 day. The solid was centrifuged and dried to obtain the target product.
[0322] Example 37: Preparation of Form E
[0323] About 10 mg of the compound represented by formula (I) was weighed and dissolved in 0.5 mL of ethyl acetate / ethanol (v / v=1:1) with stirring. The reaction solution was slurried at 25° C. for 4 days. The solid was centrifuged and dried to obtain the target product.
[0324] Example 38: Preparation of Form E
[0325] About 10 mg of the compound represented by formula (I) was weighed and dissolved in 0.5 mL of acetonitrile / methanol (v / v=1:1) with stirring. The reaction solution was slurried at 25° C. for 4 days. The solid was centrifuged and dried to obtain the target product.
[0326] Example 39: Preparation of Form E
[0327] About 10 mg of the compound represented by formula (I) was weighed and dissolved in 0.5 mL of acetonitrile / methanol (v / v=1:1) with stirring. The reaction solution was slurried at 50° C. for 1 day. The solid was centrifuged and dried to obtain the target product.
[0328] Test Example 3: Long-term accelerated test
[0329] The aforementioned Compound A hydrochloride (1:1) a crystalline form, Compound A hydrochloride (1:1) e crystalline form, Compound A hydrochloride (1:4) amorphous form, and Compound A hydrochloride (1:1) amorphous form were sealed in aluminum foil bags and placed under 25°C / 60% RH and 40°C / 75% RH conditions, respectively, to investigate their stability.
[0330] Table 21 Long-term / accelerated stability of hydrochloride (1:1) a crystal form
[0331] Table 22 Long-term / accelerated stability of hydrochloride (1:1) e crystal
[0332] Table 23 Hydrochloride (1:4) Amorphous Long-term / Accelerated Stability
[0333] Table 24 Hydrochloride (1:1) Amorphous Long-term / Accelerated Stability
[0334] Conclusion: Long-term accelerated experiments showed that the physicochemical stability of the hydrochloride (1:1) e form was good at 25°C / 60% RH and 40°C / 75% RH for 6 months, while the hydrochloride (1:1) a form, hydrochloride (1:1) amorphous form and hydrochloride (1:4) amorphous form were slightly less stable.
[0335] Test Example 4: Long-term accelerated test
[0336] The free form C of Compound A was sealed in an aluminum foil bag (nitrogen-filled for protection) and placed under conditions of 25° C. / 60% RH and 40° C. / 75% RH, respectively, to investigate the stability.
[0337] Table 25 Long-term / accelerated stability of free C crystal form
[0338] Conclusion: Long-term accelerated experiments show that the physicochemical stability of the free C crystal form is good at 25℃ / 60%RH and 40℃ / 75%RH for 6 months.
Claims
1. A crystalline form A of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 8.343, 18.020, and 21.028, preferably has characteristic peaks at 8.343, 12.559, 15.612, 18.020, and 21.028, and more preferably the X-ray powder diffraction pattern represented by the diffraction angle 2θ is as shown in Figure 2.
2. A crystalline form B of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 7.794, 15.530, 19.456, 20.559, and 21.500, preferably has characteristic peaks at 7.794, 11.832, 15.530, 19.456, 20.559, 21.500, and 29.097, more preferably has characteristic peaks at 7.794, 11.832, 12.642, 15.530, 19.456, 20.559, 21.500, and 29.097, and most preferably has an X-ray powder diffraction pattern represented by the diffraction angle 2θ as shown in Figure 3.
3. The compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 8.547, 8.847, 13.567, 15.576, and 19.169, preferably has characteristic peaks at 8.547, 8.847, 10.487, 13.567, 15.576, and 19.169, more preferably has characteristic peaks at 8.547, 8.847, 10.487, 13.567, 15.576, 19.169, and 21.973, and the most preferred X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in Figure 4.
4. A crystalline form D of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 13.834, 16.316, and 20.830, preferably at 7.928, 13.834, 16.316, and 20.
830. The X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in Figure 5.
5. The crystal form according to any one of claims 1 to 4, characterized in that The error range of the 2θ value is ±0.
2.
6. A pharmaceutically acceptable salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that The pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, succinate, meglumine, maleate, hippurate, sulfate, phosphate, methanesulfonate, tartrate, fumarate, citrate, sodium, potassium and arginine salts.
7. The pharmaceutically acceptable salt according to claim 6, characterized in that The chemical ratio of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid to the acid molecule or the base molecule is 1:0.2 to 1:5, preferably 1:0.5, 1:1, 1:2, 1:3 or 1:
4.
8. The pharmaceutically acceptable salt according to claim 6 or 7, characterized in that The chemical ratio of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and HCl is 1:1, 1:2 or 1:
3.
9. A method for preparing a pharmaceutically acceptable salt according to claim 6 or 7, characterized in that: The method comprises the step of forming a salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid with an acid or a base.
10. The method according to claim 6, characterized in that The solvent used in the salt-forming reaction is selected from at least one of ethanol, ethyl acetate, tetrahydrofuran, acetonitrile, acetone, methanol, 1,4-dioxane, 2-methyltetrahydrofuran, ethylene glycol, isopropanol and water.
11. The potassium salt α-crystalline form of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 5.544, 8.016, and 19.356, preferably has characteristic peaks at 5.544, 8.016, 19.356, and 21.537, and the X-ray powder diffraction pattern represented by the diffraction angle 2θ is more preferably as shown in Figure 6.
12. A crystalline form of the arginine salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 8.191, 10.598, 15.844, 18.447, and 20.119, preferably has characteristic peaks at 8.191, 10.598, 15.844, 18.447, 20.119, and 24.
226. More preferably, the X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in Figure 7.
13. The sodium salt of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, Form I, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 13.831 and 18.556, preferably has characteristic peaks at 7.834, 13.831, 16.194, and 18.556, and more preferably the X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in Figure 8.
14. The meglumine salt a of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 5.361, 5.879, 7.118, 8.069, 8.827, and 19.069, preferably at 5.361, 5.879, 7.118, 8.069, 8.827, 9.748, 16.230, and 19.069, more preferably at 5.361, 5.879, 7.118, 8.069, 8.827, 9.748, 13.795, 16.230, 19.069, 21.864, and 26.
223. The most preferred X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in Figure 9.
15. A crystalline form of the maleate salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 7.907, 15.612, 19.174 and 20.
701. Preferably, the X-ray powder diffraction pattern represented by the diffraction angle 2θ is as shown in FIG. 10 .
16. A crystalline form of the hippurate salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 5.551, 9.410, 13.522, 14.534, 19.956, 21.337, and 22.945, preferably at 5.551, 9.410, 11.209, 13.522, 14.175, 14.534, 19.956, 21.022, 2 There are characteristic peaks at 1.337 and 22.945, more preferably at 5.551, 9.410, 11.209, 13.522, 14.175, 14.534, 16.709, 19.956, 21.022, 21.337, and 22.945, and most preferably the X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in Figure 11.
17. A β-crystalline hippurate salt of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 4.944, 14.737, 17.143, and 20.109, preferably has characteristic peaks at 4.944, 9.978, 14.737, 17.143, and 20.109, and more preferably the X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in Figure 12.
18. The hydrochloride salt a form of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 6.385, 13.533, 16.203, and 21.244, preferably has characteristic peaks at 6.385, 8.530, 13.533, 16.203, and 21.244, and more preferably the X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in Figure 13.
19. The hydrochloride salt b form of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 8.059, 10.359, 19.412, 20.726, and 21.843, preferably has characteristic peaks at 8.059, 10.359, 16.017, 17.806, 19.412, 20.726, and 21.843, and the X-ray powder diffraction pattern represented by the diffraction angle 2θ is more preferably as shown in Figure 14.
20. The hydrochloride salt form c of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 9.395, 11.238, 13.495, and 20.153, preferably has characteristic peaks at 9.395, 11.238, 13.495, 20.153, 21.169, and 23.125, and the X-ray powder diffraction pattern represented by the diffraction angle 2θ is more preferably as shown in Figure 15.
21. The hydrochloride salt form d of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that: The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 8.128, 12.995, 14.962, 16.354, 20.401, and 23.032, preferably has characteristic peaks at 8.128, 12.216, 12.995, 14.962, 16.354, 19.268, 20.401, and 23.032, more preferably has characteristic peaks at 8.128, 12.216, 12.995, 14.962, 16.354, 19.268, 19.965, 20.401, 23.032, and 24.742, and the most preferred X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in Figure 16.
22. The hydrochloride salt form e of the compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid, characterized in that The X-ray powder diffraction pattern represented by the diffraction angle 2θ has characteristic peaks at 9.385, 14.145, 19.709, 20.277, and 21.583, preferably has characteristic peaks at 9.385, 14.145, 15.451, 19.709, 20.277, 21.583, and 23.684, more preferably has characteristic peaks at 9.385, 14.145, 15.451, 19.709, 20.277, 21.583, 23.187, 23.684, and 24.366, and the most preferred X-ray powder diffraction pattern represented by the diffraction angle 2θ is shown in Figure 17.
23. The crystalline form according to any one of claims 10 to 22, characterized in that The error range of the 2θ value is ±0.
2.
24. The crystalline form according to claims 18-22, wherein the chemical ratio of compound (2S)-3-(3-{[(2-{3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenoxy}ethyl)({3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl}methyl)amino]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid and HCl is 1:
1.
25. A pharmaceutical composition comprising the crystal form according to any one of claims 1-5 or 10-23, and a pharmaceutically acceptable excipient.
26. A pharmaceutical composition prepared from the crystal form according to any one of claims 1-5 or 10-24 and a pharmaceutically acceptable excipient.
27. Use of the pharmaceutically acceptable salt of claim 6 or 7, or the crystalline form of any one of claims 1-5 or 10-24, or the pharmaceutical composition of claim 25 or 26 in the preparation of a medicament for preventing and / or treating a disease or condition associated with elevated LP(a) levels.
28. Use of the pharmaceutically acceptable salt according to claim 6 or 7, or the crystal form according to any one of claims 1 to 5 or 10 to 24, or the pharmaceutical composition according to claim 25 or 26 in the preparation of a medicament for preventing and / or treating cardiovascular diseases.
Citation Information
Patent Citations
Pyrrolidine compounds
CN114008021A
Substituted phenylpropionic acid derivative and use thereof
WO2023078333A8
Ether compounds and compositions for cholesterol management and related uses
WO2005068410A1
Ketone compounds and compositions for cholesterol management and related uses
WO2005068412A1
Pyrrolidine compounds
WO2020247429A1
Cited By
Polycyclic derivative, and preparation method therefor and use thereof
WO2025108255A1
LP(a) inhibitor compound and use thereof
WO2025237188A1
Aromatic acid compound and medical use thereof
WO2026145708A1
